Modification of lipoproteins in uremia: Oxidation, glycation and carbamoylation

被引：13

作者：

Galle, J ^{[1
]}

Wanner, C ^{[1
]}

机构：

[1] Univ Hosp Wurzburg, Dept Med, Div Nephrol, D-97080 Wurzburg, Germany

来源：

MINERAL AND ELECTROLYTE METABOLISM | 1999年 / 25卷 / 4-6期

关键词：

oxidized LDL; uremia; glycation; atherosclerosis; glomerulosclerosis; oxidative stress; free radicals; superoxide anion;

D O I：

10.1159/000057458

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Lipoprotein modification occurs in uremic patients and in patients with end stage kidney disease under chronic renal replacement therapy. Forms of lipoprotein modification include lipid peroxidation, glycation, and carbamoylation, In this short review, we discuss the presence of these forms of lipoprotein modification and their association with various renal diseases. Methods to analyze lipoprotein modification are introduced, and functional consequences related to vascular and renal function are presented, Copyright (C) 2000 S. Karger AG, Basel.

引用

页码：263 / 268

页数：6

共 72 条

[1]

The role of oxidized lipoproteins in atherogenesis [J].

Berliner, JA ;

Heinecke, JW .

FREE RADICAL BIOLOGY AND MEDICINE, 1996, 20 (05) :707-727

[2]

GLYCOSYLATED LOW-DENSITY-LIPOPROTEIN IS MORE SENSITIVE TO OXIDATION - IMPLICATIONS FOR THE DIABETIC PATIENT [J].

BOWIE, A ;

OWENS, D ;

COLLINS, P ;

JOHNSON, A ;

TOMKIN, GH .

ATHEROSCLEROSIS, 1993, 102 (01) :63-67

[3]

Advanced glycosylation end products in diabetic renal and vascular disease [J].

Bucala, R ;

Vlassara, H .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (06) :875-888

[4]

MODIFICATION OF LOW-DENSITY-LIPOPROTEIN BY ADVANCED GLYCATION END-PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL-INSUFFICIENCY [J].

BUCALA, R ;

MAKITA, Z ;

VEGA, G ;

GRUNDY, S ;

KOSCHINSKY, T ;

CERAMI, A ;

VLASSARA, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) :9441-9445

[5]

Lipoprotein modification by advanced glycosylation endproducts (AGEs): Role in atherosclerosis [J].

Bucala, R .

TRENDS IN CARDIOVASCULAR MEDICINE, 1997, 7 (02) :39-47

[6]

REDOX STATE, ANTIOXIDATIVE ACTIVITY AND LIPID-PEROXIDATION IN ERYTHROCYTES AND PLASMA OF CHRONIC AMBULATORY PERITONEAL-DIALYSIS PATIENTS [J].

CANESTRARI, F ;

BUONCRISTIANI, U ;

GALLI, F ;

GIORGINI, A ;

ALBERTINI, MC ;

CAROBI, C ;

PASCUCCI, M ;

BOSSU, M .

CLINICA CHIMICA ACTA, 1995, 234 (1-2) :127-136

[7]

Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure [J].

CeballosPicot, I ;

WitkoSarsat, V ;

MeradBoudia, M ;

Nguyen, AT ;

Thevenin, M ;

Jaudon, MC ;

Zingraff, J ;

Verger, C ;

Jungers, P ;

DescampsLatscha, B .

FREE RADICAL BIOLOGY AND MEDICINE, 1996, 21 (06) :845-853

[8]

LP(A) LIPOPROTEIN IN CARDIOVASCULAR-DISEASE [J].

DAHLEN, GH .

ATHEROSCLEROSIS, 1994, 108 (02) :111-126

[9]

Dimmeler S, 1997, CIRCULATION, V95, P1760

[10]

NONENZYMATIC GLYCATION OF LIPOPROTEIN(A) IN-VITRO AND IN-VIVO [J].

DOUCET, C ;

HUBY, T ;

RUIZ, J ;

CHAPMAN, MJ ;

THILLET, J .

ATHEROSCLEROSIS, 1995, 118 (01) :135-143

← 1 2 3 4 5 6 7 8 →